282 related articles for article (PubMed ID: 30268859)
41. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
Ten Haaf K; Tammemägi MC; Bondy SJ; van der Aalst CM; Gu S; McGregor SE; Nicholas G; de Koning HJ; Paszat LF
PLoS Med; 2017 Feb; 14(2):e1002225. PubMed ID: 28170394
[TBL] [Abstract][Full Text] [Related]
42. Performance of 18F fluoro-2-désoxy-D-glucose positron emission tomography/computed tomography for the diagnosis of venous thromboembolism.
Le Roux PY; Robin P; Delluc A; Tardy B; Abgral R; Couturaud F; Reffad A; Le Gal G; Salaun PY
Thromb Res; 2015 Jan; 135(1):31-5. PubMed ID: 25455997
[TBL] [Abstract][Full Text] [Related]
43. Implementation of NICE recommendations on abdomino-pelvic CT, following unprovoked venous thromboembolism, in a UK teaching hospital: no additional detection of occult malignancy and high numbers of incidental findings.
Garwood D; Renton BJ; Joekes E
Acute Med; 2016; 15(5):25-9. PubMed ID: 27116584
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic value of diffusion-weighted imaging and
Noij DP; Martens RM; Zwezerijnen B; Koopman T; de Bree R; Hoekstra OS; de Graaf P; Castelijns JA
Eur J Radiol; 2018 Oct; 107():20-25. PubMed ID: 30292267
[TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
Preblick R; Kwong WJ; White RH; Goldhaber SZ
Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
[TBL] [Abstract][Full Text] [Related]
46. Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands.
Stevanović J; de Jong LA; Kappelhoff BS; Dvortsin EP; Voorhaar M; Postma MJ
PLoS One; 2016; 11(10):e0163550. PubMed ID: 27776137
[TBL] [Abstract][Full Text] [Related]
47. Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases.
Wiering B; Adang EM; van der Sijp JR; Roumen RM; de Jong KP; Comans EF; Pruim J; Dekker HM; Ruers TJ; Krabbe PF; Oyen WJ
Nucl Med Commun; 2010 Nov; 31(11):938-44. PubMed ID: 20856152
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer.
Smith AF; Hall PS; Hulme CT; Dunn JA; McConkey CC; Rahman JK; McCabe C; Mehanna H
Eur J Cancer; 2017 Nov; 85():6-14. PubMed ID: 28881249
[TBL] [Abstract][Full Text] [Related]
49. Screening and prevention of venous thromboembolism in critically ill patients: a decision analysis and economic evaluation.
Sud S; Mittmann N; Cook DJ; Geerts W; Chan B; Dodek P; Gould MK; Guyatt G; Arabi Y; Fowler RA; ;
Am J Respir Crit Care Med; 2011 Dec; 184(11):1289-98. PubMed ID: 21868500
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of Universal School- and Community-Based Vision Testing Strategies to Detect Amblyopia in Children in Ontario, Canada.
Asare AO; Maurer D; Wong AMF; Saunders N; Ungar WJ
JAMA Netw Open; 2023 Jan; 6(1):e2249384. PubMed ID: 36598785
[TBL] [Abstract][Full Text] [Related]
51. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness analysis of doctor-pharmacist collaborative prescribing for venous thromboembolism in high risk surgical patients.
Hale A; Merlo G; Nissen L; Coombes I; Graves N
BMC Health Serv Res; 2018 Oct; 18(1):749. PubMed ID: 30285744
[TBL] [Abstract][Full Text] [Related]
53. Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.
Dranitsaris G; Shane LG; Galanaud JP; Stemer G; Debourdeau P; Woodruff S
Support Care Cancer; 2017 Jul; 25(7):2093-2102. PubMed ID: 28204995
[TBL] [Abstract][Full Text] [Related]
54. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using
Greuter MJ; Schouten CS; Castelijns JA; de Graaf P; Comans EF; Hoekstra OS; de Bree R; Coupé VM
BMC Cancer; 2017 Apr; 17(1):256. PubMed ID: 28399836
[TBL] [Abstract][Full Text] [Related]
56. Screening for Occult Cancer in Patients with Venous Thromboembolism: Past, Present, and Future.
van Es N; Ay C; Jara-Palomares L
Hamostaseologie; 2020 Aug; 40(3):270-279. PubMed ID: 32726822
[TBL] [Abstract][Full Text] [Related]
57. Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism.
Coleman CI; Limone BL; Bookhart BK; Mody SH; Nutescu EA
Thromb Res; 2014 May; 133(5):743-9. PubMed ID: 24582461
[TBL] [Abstract][Full Text] [Related]
58. Colorectal cancer surveillance in patients with inflammatory bowel disease and primary sclerosing cholangitis: an economic evaluation.
Negrón ME; Kaplan GG; Barkema HW; Eksteen B; Clement F; Manns BJ; Coward S; Panaccione R; Ghosh S; Heitman SJ
Inflamm Bowel Dis; 2014 Nov; 20(11):2046-55. PubMed ID: 25230162
[TBL] [Abstract][Full Text] [Related]
59. Economic evaluation of a novel genetic screening test for risk of venous thromboembolism compared with standard of care in women considering combined hormonal contraception in Switzerland.
Sutherland CS; Ademi Z; Michaud J; Schur N; Lingg M; Bhadhuri A; Pache TD; Bitzer J; Suchon P; Albert V; Hersberger KE; Tanackovic G; Schwenkglenks M
BMJ Open; 2019 Nov; 9(11):e031325. PubMed ID: 31699733
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness of dual-head 18F-fluorodeoxyglucose PET for the detection of recurrent laryngeal cancer.
Bongers V; Hobbelink MG; van Rijk PP; Hordijk GJ
Cancer Biother Radiopharm; 2002 Jun; 17(3):303-6. PubMed ID: 12136522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
